Core Viewpoint - Replimune Group, Inc. is facing a securities fraud lawsuit following a significant stock price drop of over 70% due to the FDA's rejection of its advanced melanoma therapy application, citing insufficient clinical evidence from a Phase 2 study [2][3]. Group 1: Lawsuit Details - The lawsuit alleges that Replimune made false and misleading statements regarding the prospects of its IGNYTE trials, which were deemed inadequate by the FDA [3]. - Investors who purchased Replimune common stock between November 22, 2024, and July 21, 2025, may be eligible to participate in the lawsuit, regardless of whether they sold their shares [4]. Group 2: Next Steps for Investors - The deadline for investors to seek appointment as lead plaintiff is September 22, 2025, and a class has not yet been certified [5]. - Investors are encouraged to contact Block & Leviton for more information on how to recover losses [5]. Group 3: Whistleblower Information - Individuals with non-public information about Replimune are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 4: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].